ATM, BRCA1, BRCA2, CHEK2, PALB2 and TP53 are all established breast cancer susceptibility genes. Over the past 30 years, many other genes have been proposed as candidates. In these two large studies, the candidacy of several questionable genes has been largely resolved, and a final list of ten genes for breast and, importantly, ovarian cancer risk has emerged.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer
BMC Cancer Open Access 10 August 2023
-
Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes
Scientific Reports Open Access 26 May 2023
-
Addressing the routine failure to clinically identify monogenic cases of common disease
Genome Medicine Open Access 07 June 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hall, J. M. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684–1689 (1990).
Foulkes, W. D. & Polak, P. Journey’s end: the quest for BRCA-like hereditary breast cancer genes is nearly over. Ann. Oncol. 30, 1023–1025 (2019).
Breast Cancer Association Consortium. Breast cancer risk genes — association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 (2021).
Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 (2021).
Easton, D. et al. Gene-panel sequencing and the prediction of breast-cancer risk. New Engl. J. Med. 372, 2243–2257 (2015).
Kuchenbaecker, K. B. et al. Risks of Breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
Hughley, R. et al. Etiologic Index - A Case-Only Measure of BRCA1/2-Associated Cancer Risk. N. Engl. J. Med. 383, 286–288 (2020).
Zhao, W., Wiese, C., Kwon, Y., Hromas, R. & Sung, P. The BRCA tumor suppressor network in chromosome damage repair by homologous recombination. Annu. Rev. Biochem. 88, 221–245 (2019).
Ramus, S. J. et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J. Natl Cancer. Inst. 107, djv214 (2015).
Foulkes, W. D., Knoppers, B. M. & Turnbull, C. Population genetic testing for cancer susceptibility: founder mutations to genomes. Nat. Rev. Clin. Oncol. 13, 41–54 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Foulkes, W.D. The ten genes for breast (and ovarian) cancer susceptibility. Nat Rev Clin Oncol 18, 259–260 (2021). https://doi.org/10.1038/s41571-021-00491-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00491-3
This article is cited by
-
Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer
BMC Cancer (2023)
-
Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes
Scientific Reports (2023)
-
Addressing the routine failure to clinically identify monogenic cases of common disease
Genome Medicine (2022)
-
Prognostic Value of PFKM Polymorphisms and Susceptibility to Epithelial Ovarian Cancer in Han Women of Southwest China
Iranian Journal of Science and Technology, Transactions A: Science (2022)
-
Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
npj Breast Cancer (2021)
